MedTrace Logo

Short and Optimal Duration of Dual Antiplatelet Therapy Study

NCT01659034 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1525

Last updated 2015-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety of reduction of thienopyridine treatment period to 3 months after implantation of Cobalt-Chromium everolimus-eluting Stents.

Conditions

Interventions

DRUG

Thienopyridine for 3 months

Sponsors & Collaborators

  • Takeshi Morimoto

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD, PhD · Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659034 on ClinicalTrials.gov